Welcome to Cizzle Biotech, a spin out company from the University of York, founded around the work of Dr Dawn Coverley and colleagues. Product development is focussed on the CIZ1 gene and its potential as a diagnostic marker and therapeutic target for a variety of cancers.

The Company is supported by funds primarily from the White Rose Seed Fund, Yorkshire Cancer Research and the Viking Fund.

Cizzle’s mission is the creation of value through the development of world leading science into innovative diagnostic and therapeutic products in partnership with the biotech and pharma industries.  Its first focus is small cell lung cancer.

Cizzle Biotech
Heslington Hall, Heslington, York, North Yorkshire, Y010 5DD
UK company 5249093